期刊文献+

大剂量甲钴胺对糖尿病患者心率变异性影响的评价 被引量:3

Evaluation about Effects of Methycobal on Heart Rate Variability
原文传递
导出
摘要 目的:评价应用大剂量甲钴胺对糖尿病患者心率变异性的影响。方法:收集糖尿病患者64例,分为治疗组和对照组,治疗组患者静脉注射甲钴胺1mg,每天2次,连用2周后改为口服0.5mg,每天3次。总疗程为4周。运用24h动态心电图检测所有患者在治疗前后心率变异性指标的变化,明确甲钴胺治疗糖尿病心脏自主神经病变的疗效。结果:治疗组心率变异性各项指标治疗4周后较治疗前有显著提高,自主神经症状明显好转,与对照组比有显著统计学意义(P<0.01)。结论:甲钴胺治疗糖尿病心脏自主神经病变的疗效显著,可以改善患者的心率变异性。 Aim: To evaluate the effects of methycobal on heart rate variability(HRV) in diabetes. Methods: 64 patients were assigned to receive 1 mg methycobal bid iv for two weeks then 0.5 mg po rid. The total treatment lasted for four weeks. The change of the heart rate variability parameters of all patients was detected using 24-hour DCG (dynamic electrocardiogram), and the efficacy of methycobal on HRV in diabetics with cardiac autonomic neuropathy (CAN) was investigated. Results: In the treatment group, HRV parameters had a significant improvement after four week treatment. CAN was improved significantly, and there were significances as compared with the control group. Conclusion: Methycobal is effective for CAN in the patients with diabetes and it can improve the HRV of the patients.
出处 《中国临床神经科学》 2009年第5期475-479,共5页 Chinese Journal of Clinical Neurosciences
关键词 甲钴胺 糖尿病 心脏自主神经病变 心率变异性 methycobal diabetes cardiac autonomic neuropathy heart rate variability
  • 相关文献

参考文献9

二级参考文献25

  • 1白晓谊,黄明威,姚丽霞,韩俊平,张保敏,郭艺芳.2型糖尿病患者心率变异性的昼夜节律特征[J].中国循环杂志,2004,19(5):385-385. 被引量:2
  • 2苏建华,章莉萍,唐金荣,肖杭,包德诚.盐酸丁咯地尔对SD大鼠周围神经损害保护作用的初步实验研究[J].东南大学学报(医学版),2005,24(4):253-255. 被引量:6
  • 3周丽诺,朱禧星,范维琥.心电R-R间期频谱分析对Ⅱ型糖尿病病人心脏植物神经功能的研究[J].中国糖尿病杂志,1995,3(1):25-28. 被引量:5
  • 4周云平 张家庆.醛糖还原酶(AR)的荧光光度法测定及其在糖尿病大鼠晶体AR测定中的应用[J].中华内分泌代谢杂志,1989,5(3):159-161.
  • 5Ewing DJ, Martyn CN, Young R J, et al. The Value of Cardiovascular Autonomic Function Tests : 10Years Experience in Diabetes. Diabetes Care,1985,8:491-498.
  • 6Task Force of the European Society of Cardiology the North American Society. Heart Rate Variability: Standards of measurement, physiological interpretation, and clinical use. European Heart Journal, 1996, 17:354-381.
  • 7Hadase M,Azuma A, Zen K,et al. Very low frequency power of heart rate variability is a powerful predictor of clinical prognosis in patients with congestive heart failure. Circ J, 2004,68 : 343-347.
  • 8Perciaccante A, Fiorentini A, Paris A, et al. Circadian rhythm of the autonomic nervous system in insulin resistant subjects with normoglycemia, impaired fasting glycemia, imppaired glucose tolerance, type 2 diabetes mellitus. BMC Cardiovase Disord, 2006,6 : 2261 2471.
  • 9Gottsater A, Ahlgren AR, Taimour S, et al. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. Clin Auton Res, 2006,16:288-234.
  • 10Ruiz J, Monbaron D, Parati G, et al. Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertension, 2005,46:162-167.

共引文献37

同被引文献38

  • 1林令华,许金华,孟凡霞,李志改,于军会,杨华.依帕司他对糖尿病患者心率变异性影响的评价[J].中国医院用药评价与分析,2006,6(5):274-276. 被引量:3
  • 2黄雌友,姚伟峰,陈一丁,钱铁镛,万惠,吴卫国.α-硫辛酸治疗糖尿病自主神经病变的临床研究[J].齐齐哈尔医学院学报,2007,28(19):2314-2315. 被引量:3
  • 3Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy[J]. Diabetes Care, 2013,26 ( 5 ) : 1553-1579.
  • 4Oakley I, Emond L. Diabetic cardiac autonomic neuropathy and anesthetic management: review of the literature[J]. AANA J, 2011,79 (6) :473-479.
  • 5Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as compli- cations of diabetes mellitus[J]. Nat Rev Endocrinol, 2012,8 (7) : 405-416.
  • 6Hu X, Li S,Yang G, et al. Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy : syste- matic review and recta-analysis[J]. PLoS One, 2014,9 (2) : e87096.
  • 7Ikeda T,Iwata K,Tanaka Y. Long-term effect of epalrestat on cardiac au- tonomic neuropathy in subjects with non-insulin dependent diabetes mel- litus[J]. Diabetes Res Clin Pract, 1999,43 (3) : 193-198.
  • 8Ziegler D,Schatz H, Conrad F, et al. Effects of treatment with the antioxi- dam alpha-lipoic acid on cardiac autonomic neuropathy in NIDI)M patients. A 4-month randomized controlled multicenter trim (DEKAN Study). Deu- tsche kardiale autonome neuropathie [J]. Diabetes Care, 1997,20 (3):369- 373.
  • 9Tankova T, Koev D, Dakovska L. Alpha-lipoic acid in the treatment of au- tonomic diabetic neuropathy ( controlled, randomized, open-label study) [J]. Rom J Intern Med, 2004,42 (2) : 457-464.
  • 10Manzella D,Barbiefi M ,Ragno E,et al. Chronic administration of phar- macologic doses of vitamin E improves the cardiac autonomic nervous sys- tem in patients with type 2 diabetes[J]. Am J Clin Nutr,2001,73 (6) : 1052-1057.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部